Kaynaklar

• El Kossi M, El Nahas M. Epidemiology and pathophysiology of Chronic Kidney Disease: Natural history, risk factors and management. In Comprehensive Clinical Nephrology, Feehally J, Floege J, Johnson Rj (editors). Third ed., Philadelphia, PA: Mosby Elsevier; 2007. p. 813–21.
   Google Scholar
• Erek E, Sever MŞ, Akoglu E, Sarıyar M, Bozfakıoglu S, Apaydın S, et al. Cost of renal replacement therapy in Turkey. Nephrology 2004; 9(1): 33–8.
   PubMed Web of Science ®Google Scholar
• Egede LE. Major depression in individuals with chronic medical disorders: prevalence, correlates and association with health resource utilization, lost productivity and functional disability. Gen Hosp Psychiatry 2007; 29(5): 409–16
   PubMed Web of Science ®Google Scholar
• Kimmel PL, Peterson AR. Depression in end-stage renal disease patients treated with hemodialysis: Tools, correlates, outcomes and needs. Semin Dial 2005; 18(2): 91–7.
   PubMed Web of Science ®Google Scholar
• Hedayati SS, Minhajuddin AT, Toto RD, Morris DW, Rush AJ. Prevalence of Major Depressive Episode in CKD. Am J Kidney Dis 2009; 54(3): 424–32.
   PubMed Web of Science ®Google Scholar
• Coşkunol H, Alper Y, Akarsu D. Diyaliz hastalarında görülen psikiyatrik semptomlar. Ege Tıp Dergisi 1990; 29(4): 882–6.
   Google Scholar
• Craven JL, Rodin GM, Johnson B. The diagnosis of major depression in renal-dialysis patients. Psychosom Med 1987; 49(5): 482–92.
   Web of Science ®Google Scholar
• Daneker B, Kimmel PL, Ranich T. Depression and marital dissatisfaction in patients with end-stage renal disease and in their spouses. Am J Kid Dis, 2001; 38(4): 839–46.
   PubMed Web of Science ®Google Scholar
• Brownbridge G, Fielding DM. Factors related to psychosocial adjustment in children with end-stage renal failure. Pediatr Nephrol 1999; 13(9): 766–70.
   Web of Science ®Google Scholar
• Miller GE, Cohen S, Herbert TB. Pathways linking major depression and immunity in ambulatory female patients. Psychosom Med 1999; 61(6): 850–60.
   Web of Science ®Google Scholar
• Rothermundt M, Arolt V, Peters M, Gutbrodt H, Fenker J, Kersting A, et al. Inflammatory markers in major depression and melancholia. J Affective Disord 2001; 63(1–3): 93–102.
   PubMed Web of Science ®Google Scholar
• Huang TL, Lee CT. Low serum albumin and high ferritin levels in chronic hemodialysis patients with major depression. Psychiatry Res 2007; 152(2–3): 277–80.
   PubMed Web of Science ®Google Scholar
• Khalil AA, Frazier SK. Depressive symptoms and dietary nonadherence in patients with end-stage renal disease receiving hemodialysis: a review of quantitative evidence. Issues Ment Health Nurs 2010; 31(5): 324–30.
   PubMedGoogle Scholar
• Korkut Y. Hemodiyaliz Hastalarının Öznel Uyku Kaliteleri Üzerine Karşılaştırmalı Bir Çalışma ve Uyku Kalitesini Yordayıcı Faktörlerin Araştırılması. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 2008; 18(2): 105–112
   Google Scholar
• Drayer RA, Piraino B, Reynolds CF, Houck PR, Mazumdar S, Bernardini J, et al. Characteristics of depression in hemodialysis patients: symptoms, quality of life and mortality risk. Gen Hosp Psychiatry 2006; 28(4): 306–12.
   Web of Science ®Google Scholar
• Kennedy SH, Craven H, Roin GM. Major depression in renal dialysis patients: an open trial of antidepressant therapy. J Clin Psychiatry 1989; 50(2): 60–3.
   Web of Science ®Google Scholar
• Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medicarions: association with the use of tricyclic agents. Am J Med 2000; 108(1): 2–8.
   PubMed Web of Science ®Google Scholar
• Roose SP, Laghrissi-Thode F, Kennedy JS, Nelson JC, Bigger JT, Pollock BG, et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998; 279(4): 279–91.
   Web of Science ®Google Scholar
• Wuerth D, Finkelstein SH, Ciarcia J, Peterson R, Kliger AS, Finkelstein FO. Identification and treatment of depression in a cohort of patients maintained on chronic peritoneal dialysis. Am J Kidney Dis 2001; 37(5): 1011–7.
   Web of Science ®Google Scholar
• Spigset O, Hägg S, Stegmayr B, Dahlqvist R. Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis. Eur J Clin Pharmacol 2000; 56(9–10): 699–703.
   PubMed Web of Science ®Google Scholar
• Zung W. Self-Rating Depression Scale. Arch Gen Psychiatry 1965; 12(1): 63–70.
   PubMed Web of Science ®Google Scholar
• Williams JB. A structured interview guide for Hamilton Depression Rating Scale. Arch Gen Psychiatr 1988; 45(8): 742–7.
   PubMed Web of Science ®Google Scholar
• Akdemir A, Örsel S, Dağ İ, Türkçapar H, İçcan N, Özbay H. Hamilton depresyon derecelendirme ölçeğinin geçerliliği, güvenilirliği ve klinikte kullanımı. Psikiyatri Psikoloji Psikofarmakoloji Dergisi 1996; 4(4): 251–9.
   Google Scholar
• Hamilton M. The assesment of anxiety states by rating. Br J Med Psychol 1959; 32(1): 50–5.
   PubMed Web of Science ®Google Scholar
• Yazıcı MK, Demir B, Tanrıverdi N, Karaağaoğlu E, Yolaç P. Hamilton Anksiyete Değerlendirme Ölçeği, değerlendiriciler arası güvenilirlik ve geçerlilik çalışması. Türk Psikiyatri Dergisi 1998; 9(2): 114–7.
   Google Scholar
• Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica Suppl 1987; 334(76): 1–100.
   Google Scholar
• Chilcot J, Wellsted D, Da Silva-Gane M, Farrington K. Depression on dialysis. Nephron Clin Pract 2008; 108(4): 256–64.
   Google Scholar
• Johnson S, Dwyer A. Patient perceived barriers to treatment of depression and anxiety in hemodialysis patients. Clin Nephrol 2008; 69(3): 201–6.
   Web of Science ®Google Scholar
• Sertöz ÖÖ, Elbi MH. Bedensel hastalıklarda depresyon. Klinik Psikiyatri Dergisi 2004; 7(Suppl 2): S63–S9.
   Google Scholar
• Kalender B, Ozdemir AÇ, Yalug İ, Dervisoglu E. Antidepressant treatment ıncreases quality of life in patients with chronic renal failure. Renal Failure 2007; 29(7): 817–22.
   PubMed Web of Science ®Google Scholar
• Hytell J, Bogeso KP, Perregard J, Sanchez C. The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer. J Neural Transm 1992; 88(2): 157–60.
   Web of Science ®Google Scholar
• Mørk A, Kreilgaard M, Sánchez C. In vitro and in vivo effects of escitalopram and its enantiomers on the serotonin uptake transporter. Eur Neuropsychopharmacol 2002; 12(3): 224.
   Google Scholar
• Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001; 50(5): 345–50.
   PubMed Web of Science ®Google Scholar
• Wade AG, Lemming O, Hedegaard K. Escitalopram 10 mg/day is an effective and well-tolerated first-line antidepressant in primary care. Int Clin Psychopharmacol 2002; 17(3): 95–102.
   Web of Science ®Google Scholar
• Gorman J, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: Pooled analysis of placebo-controlled trials. CNS Spect. 2002; 7(4 Suppl 1): S40–S4.
   PubMed Web of Science ®Google Scholar
• Lepola UM, Loft H, Reiness EH. Escitalopram (10–20mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003; 18(4): 211–7.
   PubMed Web of Science ®Google Scholar
• Loosman WL, Siegert CE, Korzec A, Honig A. Validity of the Hospital Anxiety and Depression Scale and the Beck Depression Inventory for use in end-stage renal disease patients. Br J Clin Psychol 2010; 49(4): 507–16.
   PubMedGoogle Scholar
• İnce E, Çifter İ. Uzun süreli hemodiyaliz hastaları ile romatoid artrit tanısı almış hastaların rıhsal bozukluklar açısından karşılaştırılması. Kriz Dergisi 1995; 3(1–2): 265–9.
   Google Scholar
• Cukor D, Coplan J, Brown C, Friedman S, Newville H, Safier M, et al. Anxiety Disorders in Adults Treated by Hemodialysis: A SingleCenter Study. Am J Kidney Dis 2008; 52(1): 128–36.
   PubMed Web of Science ®Google Scholar
• Burke W. Fixed dose study of escitalopram in the treatment of depression, Poster present at the Annual Metting of the American College of Neuropsychopharmacology (ACNP), Puerto Rico: 2000: 10–14
   Google Scholar
• Rush J, Bose A. Escitalopram in clinical practice: results of an open-label trial in naturalistic setting. Depress Anxiety 2005; 21(1): 26–32.
   Web of Science ®Google Scholar
• Gorman JM. Comorbid depression and anxiety spectrum disorders. Depress Anxiety 1996–97; 4(4): 160–8.
   PubMedGoogle Scholar
• Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63(4): 331–6.
   PubMed Web of Science ®Google Scholar
• Lepola U, Loft H, Reines EH. Escitalopram is efficacious and well tolerated for the treatment of depression in primary care. Eur Neuropsyhopharmacol 2001; 11(3): 232.
   Google Scholar
• Rush J, Bose A. Escitalopram in clinical practice: results of an open-label trial in naturalistic setting. Depress Anxiety 2005; 21(1): 26–32.
   Web of Science ®Google Scholar
• Al-Hilali N, Al-Humoud HM, Ninan VT. Profiled Hemodialysis Reduced Intradialytic Symptoms. Transplant Proc 2004; 36(6): 1827–8.
   Web of Science ®Google Scholar